The Valecor Platinum Coronary Stent System represents a major advancement over current offerings in the relatively undifferentiated $1 billion bare stent market, said S. Eric Ryan, M.D., chairman and chief executive officer of CorNova. Because of its highly biocompatible platinum surface and its novel open cell design, it has shown superior anti-restentotic performance compared to leading bare metal stents in preclinical studies.
